NewsBenzingaEastern Bankshares第三季度调整后每股收益0.51美元,超出0.49美元预期;销售额3.066亿美元,超出2.67631亿美元预期 Eastern Bankshares第三季度调整后每股收益0.51美元,超出0.49美元预期;销售额3.066亿美元,超出2.67631亿美元预期 Benzinga 2026.10.22 20:16 (GMT+0) Open on Benzinga Other news Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why Binance Plans to Expand into Five Asian Markets Next Year, Focusing on South and Southeast Asia Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated
Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled
FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage
SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why
Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity
Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated